AV133 PET scan study in early Parkinson's disease
Part of Brain & nervous system clinical trials.
This study uses a special PET scan to look at a protein (VMAT2) in the brain that is linked to Parkinson's disease. It helps researchers understand early changes in people with newly diagnosed Parkinson's or those at high risk of developing it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 30 years or older (for Parkinson's disease) or 60 years or older (for early signs without diagnosis).
- You have been diagnosed with Parkinson's disease within the last 2 years and are in the early stage (Hoehn & Yahr stage I or II), OR you have early signs such as loss of smell and a family history or genetic risk for Parkinson's.
- You are not currently taking any Parkinson's disease medications like levodopa, dopamine agonists, or MAO-B inhibitors.
- You are willing to stop certain medications (like some blood pressure or stimulant drugs) that can interfere with the PET scan, if needed.
- You do not have dementia or other significant memory problems, and you do not have a heart condition or take medications that affect heart rhythm.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special PET scan to look at inflammation in the brain of people with Parkinson's disease or those at risk for it. The goal is to better understand the disease and possibly find new ways to track its progression.
This research study tests a new type of brain scan (called a PET scan) that may help detect early signs of Parkinson's disease and similar conditions. You'll receive the scan and may have a spinal tap to check for specific protein markers.
This study uses a special type of brain scan (PET/CT) to look at a protein called MAO-B in people with Parkinson's disease or related conditions. The scan may help doctors understand more about the disease and could be part of your regular care.
This trial tests how well special brain scans (PET/SPECT) and spinal fluid tests can show changes in people with inherited (genetic) Parkinson’s. It may help researchers understand what’s happening in the brain and improve how these conditions are measured.
This study is building a large, detailed group of people—some with Parkinson’s and some at higher risk—to understand early changes over time. It uses brain imaging (DaTscan SPECT), sometimes spinal fluid tests (lumbar puncture), and genetic information to help researchers better measure disease and develop future treatments.
This study uses special scans to measure how serotonin is released in parts of the brain involved in movement in Parkinson’s disease. It may help researchers understand disease changes and the role of serotonin systems in movement problems.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.